UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 184

Sortiert nach

Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes

Annals of oncology, 2005-12, Vol.16 (12), p.1921-1927

2005

Link zum Volltext

Verfügbarkeit prüfen

Skin testing and hypersensitivity reactions to oxaliplatin

Annals of oncology, 2003-03, Vol.14 (3), p.497-498

2003

Link zum Volltext

Verfügbarkeit prüfen

P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: Distribution and prognostic relevance

European journal of cancer (1990), 2008-06, Vol.44 (9), p.1217-1222

2008

Link zum Volltext

Verfügbarkeit prüfen

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

British journal of cancer, 2006-06, Vol.94 (12), p.1789-1796

2006

Link zum Volltext

Verfügbarkeit prüfen

Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing

Annals of oncology, 2004-11, Vol.15 (11), p.1684-1690

2004

Link zum Volltext

Verfügbarkeit prüfen

Cancer-related fatigue: Evolving concepts in evaluation and treatment

Cancer, 2003-11, Vol.98 (9), p.1786-1801

2003

Link zum Volltext

Verfügbarkeit prüfen

Factorial design for randomized clinical trials

Annals of oncology, 2006-10, Vol.17 (10), p.1607-1608

2006

Link zum Volltext

Verfügbarkeit prüfen

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma

British journal of cancer, 2002-03, Vol.86 (6), p.999-1005

2002

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer

Annals of oncology, 2004-03, Vol.15 (3), p.433-439

2004

Link zum Volltext

Verfügbarkeit prüfen

Malignant glucagonoma. New options of treatment

Journal of experimental & clinical cancer research, 2006-03, Vol.25 (1), p.135-139

2006

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients

British journal of cancer, 2003-11, Vol.89 (10), p.1870-1875

2003

Link zum Volltext

Verfügbarkeit prüfen

Immunohemolytic anemia following oxaliplatin administration

Annals of oncology, 2000-04, Vol.11 (4), p.497-497

2000

Link zum Volltext

Verfügbarkeit prüfen

Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study

Annals of oncology, 2001-02, Vol.12 (2), p.179-182

2001

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel-induced nail changes : possible role of its vehicle (cremophor el)

EJD. European journal of dermatology, 2006-11, Vol.16 (6), p.693-694

2006

Link zum Volltext

Verfügbarkeit prüfen

Non-small cell lung cancer: early stages

Annals of oncology, 2006-04, Vol.17 (suppl-2), p.ii17-ii21

2006

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer

Annals of oncology, 1998-11, Vol.9 (11), p.1199-1204

1998

Link zum Volltext

Verfügbarkeit prüfen

Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening?

Gut, 2005-06, Vol.54 (6), p.891-891

2005

Link zum Volltext

Verfügbarkeit prüfen

Pilot study of celecoxib and infusional 5‐fluorouracil as second‐line treatment for advanced pancreatic carcinoma

Cancer, 2004-07, Vol.101 (1), p.133-138

2004

Link zum Volltext

Verfügbarkeit prüfen

Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide

Journal of clinical oncology, 2005-10, Vol.23 (28), p.6908-6918

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer

Annals of oncology, 1999-08, Vol.10 (8), p.937-942

1999

Link zum Volltext

Verfügbarkeit prüfen

Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients

Journal of neurology, neurosurgery and psychiatry, 1996-10, Vol.61 (4), p.409-411

1996

Link zum Volltext

Verfügbarkeit prüfen

Response to recombinant human erythropoietin in patients with myelodysplastic syndromes

Clinical cancer research, 1997-05, Vol.3 (5), p.733-739

1997

Link zum Volltext

Verfügbarkeit prüfen

6576 POSTER Extent of mediastinal lymph-nodes resection as prognostic factor for survival in stage I–IIIA non-small-cell lung cancer (NSCLC) patients undergone surgery: a retrospective analysis of a mono-institutional series

European journal of cancer supplements, 2007, Vol.5 (4), p.381-381

2007

Link zum Volltext

Verfügbarkeit prüfen

Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes

Blood, 2002-03, Vol.99 (5), p.1578-1584

2002

Link zum Volltext

Verfügbarkeit prüfen

Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide

Journal of clinical oncology, 2003-09, Vol.21 (18), p.3462-3468

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 184

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(153)
Mit Volltextzugriff
(141)

Publikationsform

Artikel
(173)
Buchkapitel
(10)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(98)
Female
(71)
Science & Technology
(68)
Life Sciences & Biomedicine
(67)
Middle Aged
(54)
Aged
(49)
Biological And Medical Sciences
(48)
Medical Sciences
(48)
Male
(45)
Adult
(44)
Oncology
(43)
Pharmacology. Drug Treatments
(28)
Breast Neoplasms - Drug Therapy
(25)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(22)
Treatment Outcome
(21)
Antineoplastic Agents
(16)
Drug Administration Schedule
(16)
Tumors
(16)
Adolescent
(12)
Breast Neoplasms - Pathology
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes

Skin testing and hypersensitivity reactions to oxaliplatin

P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: Distribution and prognostic relevance

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing

Cancer-related fatigue: Evolving concepts in evaluation and treatment

Factorial design for randomized clinical trials

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer

Malignant glucagonoma. New options of treatment

A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients

Immunohemolytic anemia following oxaliplatin administration

Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study

Paclitaxel-induced nail changes : possible role of its vehicle (cremophor el)

Non-small cell lung cancer: early stages

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer

Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening?

Pilot study of celecoxib and infusional 5‐fluorouracil as second‐line treatment for advanced pancreatic carcinoma

Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide

Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer

Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients

Response to recombinant human erythropoietin in patients with myelodysplastic syndromes

6576 POSTER Extent of mediastinal lymph-nodes resection as prognostic factor for survival in stage I–IIIA non-small-cell lung cancer (NSCLC) patients undergone surgery: a retrospective analysis of a mono-institutional series

Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes

Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide

Suchergebnisse filtern